3 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hemangioma, Cavernous, Central Nervous System: new trials by email Literature Review of Hemangioma, Cavernous, Central Nervous System trials Research Report on Hemangioma, Cavernous, Central Nervous System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 REC-994, Placebo - Cerebral Cavernous Malformation | Phase 2 | Completed | Recursion Pharmaceuticals Inc. | 62 | 2022-03-17 | 2026-10-22 |
| Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial Atorvastatin, Placebo - Cerebral Cavernous Malformation | Phase 1 / Phase 2 | Completed | University of Chicago | 80 | 2018-07-17 | 2025-08-22 |
| Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation Propranolol - Cerebral Cavernous Malformation | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 71 | 2018-04-11 | 2022-02-25 |
| Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation Propranolol, DNA and RNA Analysis - Cerebral Cavernous Malformations | Phase 2 | Terminated | St. Joseph's Hospital and Medical Center, Phoenix | 4 | 2018-01-24 | 2024-04-19 |
Brain Diseases (4) · Cardiovascular Abnormalities (4) · Cardiovascular Diseases (4) · Cavernous Sinus Syndromes (4) · Central Nervous System Diseases (4) · Central Nervous System Vascular Malformations (4) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Hemangioma (4) · Hemangioma, Cavernous (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Neoplasms (4)
Propranolol (2) · Atorvastatin (1) · DNA (1)
Mario Negri Institute for Pharmacological Research (1) · Recursion Pharmaceuticals Inc. (1) · St. Joseph's Hospital and Medical Center, Phoenix (1) · University of Chicago (1)
United States (3) · Italy (1)
Daniel F Hanley, MD (1) · Elisabetta Dejana, Professor (1) · Issam A Awad, MD (1) · Joseph Zabramski, MD (1) · Roberto Latini (1)
PMID 32398113, PMID 36403580, PMID 38419711, PMID 40120614, PMID 40570636, PMID 41117517, PMID 41608890
2017 (1)